DUBLIN--(BUSINESS WIRE)--The "Antipsychotic Drugs: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering.
This report provides a detailed description of the market for antipsychotic drugs. The report highlights the current and future market potential of antipsychotic drugs and provides a detailed analysis of the competitive environment, regulatory scenario, technological advancements, patent analysis, pipeline analysis, drivers, restraints, opportunities and trends in the market. The report also covers market projections through 2023, as well as market shares for key market players. The report segments the market for antipsychotic drugs based on the mechanism of action, disease indication and geography.
Based on the mechanism of action, the market is segmented into D2 antagonists, D2/5HT2A antagonists and D2 partial agonists. The market size includes both branded and generic drugs. Based on disease indication, the market is segmented into schizophrenia, bipolar disorder, major depressive disorder (MDD), and other diseases including anxiety, autism and dementia.
By geography, the market has been segmented into the North America, Europe, Asia-Pacific, South America, and Middle East and Africa regions. The North America region includes the U.S., Canada and Mexico. Europe includes Germany, the U.K., France, Italy, Spain and the rest of Europe. Asia-Pacific includes China, India, Japan and the rest of Asia-Pacific. For market estimates, data has been provided for 2017 as the base year, with forecasts for 2018 through 2023.
The Report Includes:
- Analyses of global market trends, with data from 2017, estimates for 2018 and projections of CAGRs through 2023
- Country specific data and analysis for United States, Canada, Mexico, UK, France, Germany, Italy, Spain, China, India and Japan
- Definition, history and types of antipsychotic drugs
- An understanding on receptor target of antipsychotic drugs, including dopamine, serotonin, glutamate, tachykinin and glucocorticoid
- Coverage of various psychotic diseases and their indication including schizophrenia, bipolar disorder, major depressive disorder (MDD), anxiety, autism and dementia
- Comprehensive company profiles of key players in the market, including Alexza Pharmaceuticals, Dr. Reddy's Laboratories, Ltd., Eli Lilly and Co., Johnson & Johnson, Teva Pharmaceutical Industries, Ltd., and Zydus Pharmaceuticals (USA), Inc.
Key Topics Covered:
Chapter 1 Introduction
Chapter 2 Summary And Highlights
Chapter 3 Market And Technology Background
Chapter 4 Market Dynamics
Chapter 5 Market Breakdown By Mechanism Of Action
Chapter 6 Market Breakdown By Disease Indication
Chapter 7 Market Breakdown By Region
Chapter 8 Regulatory Scenario
Chapter 9 Patent Analysis
Chapter 10 Pipeline Analysis
Chapter 11 Competitive Landscape
Chapter 12 Company Profiles
- Acadia Pharmaceuticals, Inc.
- Alembic Pharmaceuticals, Ltd.
- Alexza Pharmaceuticals
- Alkermes Plc
- Allergan Plc
- Apotex, Inc.
- Astrazeneca Plc
- Aurobindo Pharma
- Dr. Reddy's Laboratories Ltd.
- Eli Lilly and Co
- Gedeon Richter Plc
- H. Lundbeck A/S
- Johnson & Johnson
- Lannett Co., Inc.
- Lupin, Ltd.
- Mayne Pharma, Inc.
- Mylan Nv
- Otsuka Holdings Co., Ltd.
- Sumitomo Dainippon Pharma Co., Ltd.
- Sun Pharmaceutical Industries Limited (Sun Pharma)
- Teva Pharmaceutical Industries, Ltd
- Torrent Pharmaceuticals, Ltd.
- Vanda Pharmaceuticals, Inc
- Wockhardt
-
Zydus Pharmaceuticals (USA), Inc.
For more information about this report visit https://www.researchandmarkets.com/research/vtb55w/antipsychotic?w=4
